About Modulo Bio
Modulo Bio is a San Diego-based biotechnology company focused on harnessing the power of the neuroimmune system to develop treatments for neurodegenerative diseases such as ALS and frontotemporal dementia (FTD). Its proprietary Modulo Neuroimmune Platform combines patient-derived stem cell engineering, neuroscience, multiomics, and AI to model microglial behavior and identify drug targets. The company's lead asset, MOD 001, is a small molecule CSF1R inhibitor designed to modulate microglial function and penetrate the blood-brain barrier.
Company details
Funding
Total raised
$22.6M
Last stage
Seed
Investors
Founders
Michael Horowitz
CEO and co-founder of Modulo Bio. His personal motivation for founding the company stems from a close friend's family member developing frontotemporal dementia (FTD).
Scott Patterson
Co-founder and CTO of Modulo Bio. Previously served as Vice President of Engineering at Counsyl. Seasoned technologist focused on AI-driven neuroimmune drug discovery.
LinkedInJustin Ichida
PhD, Professor at the University of Southern California (USC). Scientific founder of Modulo Bio and a recognized leader in modeling ALS and FTD using patient-derived cells.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.